Michelle Glass
Michelle Glass
Verified email at otago.ac.nz
Cited by
Cited by
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
M Glass, RLM Faull, M Dragunow
Neuroscience 77 (2), 299-318, 1997
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor
M Glass, CC Felder
Journal of Neuroscience 17 (14), 5327-5333, 1997
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor
NE Buckley, KL McCoy, ╔ Mezey, T Bonner, A Zimmer, CC Felder, ...
European journal of pharmacology 396 (2-3), 141-149, 2000
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia iná…
M Glass, M Dragunow, RLM Faull
Neuroscience 97 (3), 505-519, 2000
Cannabinoid receptors and their endogenous agonists
CC Felder, M Glass
Annual review of pharmacology and toxicology 38 (1), 179-200, 1998
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?
CS Kearn, K Blake-Palmer, E Daniel, K Mackie, M Glass
Molecular pharmacology 67 (5), 1697-1704, 2005
Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors
M Glass, JK Northup
Molecular pharmacology 56 (6), 1362-1369, 1999
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation
CC Felder, KE Joyce, EM Briley, M Glass, KP Mackie, KJ Fahey, ...
Journal of Pharmacology and Experimental Therapeutics 284 (1), 291-297, 1998
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
JC Ashton, M Glass
Current neuropharmacology 5 (2), 73-80, 2007
Loss of cannabinoid receptors in the substantia nigra in Huntington's disease
M Glass, RLM Faull, M Dragunow
Neuroscience 56 (3), 523-527, 1993
Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences
JM McPartland, M Glass, RG Pertwee
British journal of pharmacology 152 (5), 583-593, 2007
CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids
SD McAllister, M Glass
Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 66 (2-3), 161-171, 2002
The endocannabinoid system as a target for the treatment of neurodegenerative disease
EL Scotter, ME Abood, M Glass
British journal of pharmacology 160 (3), 480-498, 2010
Cannabis, cannabinoids and reproduction
B Park, JM McPartland, M Glass
Prostaglandins, leukotrienes and essential fatty acids 70 (2), 189-197, 2004
Evolutionary origins of the endocannabinoid system
JM McPartland, I Matias, V Di Marzo, M Glass
Gene 370, 64-74, 2006
Delayed onset of huntington′ s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors
M Glass, A Van Dellen, C Blakemore, AJ Hannan, RLM Faull
Neuroscience 123 (1), 207-212, 2004
Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain
JC Ashton, RMA Rahman, SM Nair, BA Sutherland, M Glass, I Appleton
Neuroscience letters 412 (2), 114-117, 2007
Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta
B Park, HM Gibbons, MD Mitchell, M Glass
Placenta 24 (10), 990-995, 2003
Neurochemical and morphological changes associated with human epilepsy
M Glass, M Dragunow
Brain research reviews 21 (1), 29-41, 1995
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, andá…
SD Banister, M Longworth, R Kevin, S Sachdev, M Santiago, J Stuart, ...
ACS chemical neuroscience 7 (9), 1241-1254, 2016
The system can't perform the operation now. Try again later.
Articles 1–20